The evolution of combined molecular targeted therapies to advance the therapeutic efficacy in melanoma: a highlight of vemurafenib and cobimetinib

por Medina, Theresa M, Lewis, Karl D
Publicado 2016

BRAF/MEK inhibitor-induced remission of primary cutaneous myoepithelial carcinoma after local recurrence

por Guidry, Jacqueline, Lewis, Karl, Brown, Mariah
Publicado 2020

Brief overview: cemiplimab for the treatment of advanced basal cell carcinoma: PD-1 strikes again

por Davis, Christina M., Lewis, Karl D.
Publicado 2022

Pegylated interferon alpha-2b as adjuvant treatment of Stage III malignant melanoma: an evidence-based review

por Okuyama, Sonia, Gonzalez, Rene, Lewis, Karl D
Publicado 2010

Effects of Sonidegib Following Dose Reduction and Treatment Interruption in Patients with Advanced Basal Cell Carcinoma During 42-Month BOLT Trial

por Lewis, Karl, Dummer, Reinhard, Farberg, Aaron S., Guminski, Alexander, Squittieri, Nicholas, Migden, Michael
Publicado 2021

Twist1 Inactivation in Dmp1-Expressing Cells Increases Bone Mass but Does Not Affect the Anabolic Response to Sclerostin Neutralization

por Lewis, Karl J., Choi, Roy B-J, Pemberton, Emily Z., Bullock, Whitney A., Firulli, Anthony B., Robling, Alexander G.
Publicado 2019

The mTORC2 Component Rictor Is Required for Load‐Induced Bone Formation in Late‐Stage Skeletal Cells

por Lewis, Karl J, Yi, Xin, Wright, Christian S, Pemberton, Emily Z, Bullock, Whitney A, Thompson, William R, Robling, Alexander G
Publicado 2020

Key Clinical Adverse Events in Patients with Advanced Basal Cell Carcinoma Treated with Sonidegib or Vismodegib: A Post Hoc Analysis

por Gutzmer, Ralf, Loquai, Carmen, Robert, Caroline, Dréno, Brigitte, Guminski, Alexander, Lewis, Karl, Arntz, Ramon, Martelli, Serena, Squittieri, Nicholas, Kheterpal, Meenal
Publicado 2021

Immune checkpoint inhibitor therapy in HIV-associated Merkel cell carcinoma: A case series of 3 patients

por Park, Song Y., Church, Candice, Alexander, Nora A., Shinohara, Michi M., Paulson, Kelly G., Lewis, Karl D., Lee, Nancy S., Nghiem, Paul
Publicado 2020

Stereotactic body radiation therapy for melanoma and renal cell carcinoma: impact of single fraction equivalent dose on local control

por Stinauer, Michelle A, Kavanagh, Brian D, Schefter, Tracey E, Gonzalez, Rene, Flaig, Thomas, Lewis, Karl, Robinson, William, Chidel, Mark, Glode, Michael, Raben, David
Publicado 2011

Spatial mapping of polymicrobial communities reveals a precise biogeography associated with human dental caries

por Kim, Dongyeop, Barraza, Juan P., Arthur, Rodrigo A., Hara, Anderson, Lewis, Karl, Liu, Yuan, Scisci, Elizabeth L., Hajishengallis, Evlambia, Whiteley, Marvin, Koo, Hyun
Publicado 2020

ABT-737 synergizes with Bortezomib to kill melanoma cells

por Reuland, Steven N., Goldstein, Nathaniel B., Partyka, Katie A., Smith, Shilo, Luo, Yuchun, Fujita, Mayumi, Gonzalez, Rene, Lewis, Karl, Norris, David A., Shellman, Yiqun G.
Publicado 2011

Safety and efficacy of vismodegib in patients aged ≥65 years with advanced basal cell carcinoma

por Chang, Anne Lynn S., Lewis, Karl D., Arron, Sarah T., Migden, Michael R., Solomon, James A., Yoo, Simon, Day, Bann-Mo, McKenna, Edward F., Sekulic, Aleksandar
Publicado 2016

Impact of initial treatment and prognostic factors on postprogression survival in BRAF-mutated metastatic melanoma treated with dacarbazine or vemurafenib ± cobimetinib: a pooled a...

por Ascierto, Paolo A., Ribas, Antoni, Larkin, James, McArthur, Grant A., Lewis, Karl D., Hauschild, Axel, Flaherty, Keith T., McKenna, Edward, Zhu, Qian, Mun, Yong, Dréno, Brigitte
Publicado 2020

Targeting wild-type TP53 using AMG 232 in combination with MAPK inhibition in Metastatic Melanoma; a phase 1 study

por Moschos, Stergios J., Sandhu, Shahneen, Lewis, Karl D., Sullivan, Ryan J., Puzanov, Igor, Johnson, Douglas B., Henary, Haby A., Wong, Hansen, Upreti, Vijay V., Long, Georgina V., Flaherty, Keith T.
Publicado 2022

Impact of depth of response on survival in patients treated with cobimetinib ± vemurafenib: pooled analysis of BRIM-2, BRIM-3, BRIM-7 and coBRIM

por Lewis, Karl D., Larkin, James, Ribas, Antoni, Flaherty, Keith T., McArthur, Grant A., Ascierto, Paolo A., Dréno, Brigitte, Yan, Yibing, Wongchenko, Matthew, McKenna, Edward, Zhu, Qian, Mun, Yong, Hauschild, Axel
Publicado 2019

A Phase II Study of Glembatumumab Vedotin for Metastatic Uveal Melanoma

por Hasanov, Merve, Rioth, Matthew J., Kendra, Kari, Hernandez-Aya, Leonel, Joseph, Richard W., Williamson, Stephen, Chandra, Sunandana, Shirai, Keisuke, Turner, Christopher D., Lewis, Karl, Crowley, Elizabeth, Moscow, Jeffrey, Carter, Brett, Patel, Sapna
Publicado 2020

ARRY-382 in Combination with Pembrolizumab in Patients with Advanced Solid Tumors: Results from a Phase 1b/2 Study

por Johnson, Melissa, Dudek, Arkadiusz Z., Sukari, Ammar, Call, Justin, Kunk, Paul R., Lewis, Karl, Gainor, Justin F., Sarantopoulos, John, Lee, Patrice, Golden, Adele, Harney, Allison, Rothenberg, S. Michael, Zhang, Yuanyuan, Goldman, Jonathan W.
Publicado 2022

Retrospective Analysis of the Safety and Efficacy of High-dose Interleukin-2 After Prior Tyrosine Kinase Inhibitor Therapy in Patients With Advanced Renal Cell Carcinoma

por Lam, Elaine T., Wong, Michael K. K., Agarwal, Neeraj, Redman, Bruce G., Logan, Theodore, Gao, Dexiang, Flaig, Thomas W., Lewis, Karl, Poust, Jamie, Monk, Paul, Jarkowski, Anthony, Sendilnathan, Arun, Bolden, Marcus, Kuzel, Timothy M., Olencki, Thomas
Publicado 2014

Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial

por Kaufman, Howard L., Russell, Jeffery S., Hamid, Omid, Bhatia, Shailender, Terheyden, Patrick, D’Angelo, Sandra P., Shih, Kent C., Lebbé, Céleste, Milella, Michele, Brownell, Isaac, Lewis, Karl D., Lorch, Jochen H., von Heydebreck, Anja, Hennessy, Meliessa, Nghiem, Paul
Publicado 2018